LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial

समान संसाधन

• Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
  द्वारा: Lapuerta, Pablo, और अन्य
  प्रकाशित: (2013)
• Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
  द्वारा: Rosenstock, Julio, और अन्य
  प्रकाशित: (2015)
• The Tryptophan Hydroxylase Inhibitor LX1031 Shows Clinical Benefit in Patients With Nonconstipating Irritable Bowel Syndrome
  द्वारा: Brown, Philip M., और अन्य
  प्रकाशित: (2011)
• LP-925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT1 and SGLT2
  द्वारा: Powell, David R, और अन्य
  प्रकाशित: (2015)
• Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
  द्वारा: Sands, Arthur T., और अन्य
  प्रकाशित: (2015)